JPS637545B2 - - Google Patents
Info
- Publication number
- JPS637545B2 JPS637545B2 JP56169392A JP16939281A JPS637545B2 JP S637545 B2 JPS637545 B2 JP S637545B2 JP 56169392 A JP56169392 A JP 56169392A JP 16939281 A JP16939281 A JP 16939281A JP S637545 B2 JPS637545 B2 JP S637545B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- hydrogen
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 13
- 150000002431 hydrogen Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- -1 methoxyphenyl Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 4
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical compound OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 2
- 230000000803 paradoxical effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003140 primary amides Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MKABYAVQDNWADL-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CC1=C(C=2C=CC(Cl)=CC=2)N=C2N1C=CC=C2 MKABYAVQDNWADL-UHFFFAOYSA-N 0.000 description 1
- ZOUWHRHJCHJSGJ-UHFFFAOYSA-N 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]acetamide Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N)=C1C1=CC=C(Cl)C=C1 ZOUWHRHJCHJSGJ-UHFFFAOYSA-N 0.000 description 1
- PAPIVHGHEPOCNK-UHFFFAOYSA-N 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C1=C(CC#N)N2C=C(Cl)C=CC2=N1 PAPIVHGHEPOCNK-UHFFFAOYSA-N 0.000 description 1
- YDHIMEXEGOCNHU-UHFFFAOYSA-N 2-pyridin-3-ylacetamide Chemical compound NC(=O)CC1=CC=CN=C1 YDHIMEXEGOCNHU-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000026680 Metabolic Brain disease Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8022537A FR2492382A1 (fr) | 1980-10-22 | 1980-10-22 | Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5798283A JPS5798283A (en) | 1982-06-18 |
| JPS637545B2 true JPS637545B2 (enExample) | 1988-02-17 |
Family
ID=9247171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56169392A Granted JPS5798283A (en) | 1980-10-22 | 1981-10-21 | Imidazopyridine derivative |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US4382938A (enExample) |
| EP (1) | EP0050563B1 (enExample) |
| JP (1) | JPS5798283A (enExample) |
| AT (1) | ATE7393T1 (enExample) |
| AU (1) | AU544345B2 (enExample) |
| CA (1) | CA1157470A (enExample) |
| DE (1) | DE3163524D1 (enExample) |
| DK (1) | DK154429C (enExample) |
| ES (1) | ES8207537A1 (enExample) |
| FI (1) | FI71143C (enExample) |
| FR (1) | FR2492382A1 (enExample) |
| GR (1) | GR74701B (enExample) |
| IE (1) | IE51686B1 (enExample) |
| IL (1) | IL64091A (enExample) |
| LU (1) | LU88228I2 (enExample) |
| MX (1) | MX6463E (enExample) |
| NL (1) | NL930044I2 (enExample) |
| NO (1) | NO155664C (enExample) |
| NZ (1) | NZ198722A (enExample) |
| OA (1) | OA07076A (enExample) |
| PT (1) | PT73863B (enExample) |
| ZA (1) | ZA817297B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011026299A (ja) * | 2009-06-25 | 2011-02-10 | Takada Seiyaku Kk | ゾルピデム酒石酸塩含有内用液剤 |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525601A1 (fr) * | 1982-04-21 | 1983-10-28 | Synthelabo | Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| FR2525602A1 (fr) * | 1982-04-21 | 1983-10-28 | Synthelabo | Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| FR2568879B1 (fr) * | 1984-08-07 | 1986-12-12 | Synthelabo | Imidazo(1,2-a)quinolines, leur preparation et leur application en therapeutique |
| FR2581646B1 (fr) * | 1985-05-07 | 1987-09-18 | Synthelabo | Derives d'imidazopyridine, leur preparation et leur application en therapeutique |
| FR2593179B1 (fr) * | 1986-01-22 | 1988-04-01 | Synthelabo | Derives d'imidazo(1,2-a)quinoleines, leur preparation et leur application en therapeutique |
| ES2032455T3 (es) * | 1986-01-22 | 1993-02-16 | Synthelabo | Procedimiento para preparar derivados de 3-acilaminometil-imidazo (-1,2-a)piridinas. |
| FR2593817B1 (fr) * | 1986-01-31 | 1988-04-15 | Synthelabo | Derives de tetrahydro-5,6,7,8 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique |
| FR2599368B1 (fr) * | 1986-06-02 | 1988-08-05 | Synthelabo | Derives hydroxyles d'imidazopyridines, leur preparation et leur application en therapeutique |
| FR2600650B1 (fr) * | 1986-06-27 | 1988-09-09 | Synthelabo | Procede de preparation d'imidazopyridines et composes intermediaires |
| FR2606409B1 (fr) * | 1986-11-07 | 1989-05-05 | Synthelabo | Derives d'imidazopyridine, leur preparation et leur application en therapeutique |
| FR2606411B1 (fr) * | 1986-11-07 | 1989-04-07 | Synthelabo | Imidazopyridine-acetamides, leur preparation et leur application en therapeutique |
| FR2606410B1 (fr) * | 1986-11-07 | 1989-02-24 | Synthelabo | Imidazopyridines, leur preparation et leur application en therapeutique |
| EP0289371B1 (fr) * | 1987-03-27 | 1991-09-25 | Synthelabo | Dérivés d'imidazopyridines, leur préparation et leur application en thérapeutique |
| FR2612928B1 (fr) * | 1987-03-27 | 1989-06-16 | Synthelabo | Derives hydroxyles d'imidazopyridines, leur preparation et leur application en therapeutique |
| FR2612927B1 (fr) * | 1987-03-27 | 1989-06-09 | Synthelabo | Derives d'imidazopyridines, leur preparation et leur application en therapeutique |
| US5032595A (en) * | 1989-11-24 | 1991-07-16 | Fidia-Georgetown Institute For The Neurosciences | Method of stimulating steroidogenesis with alpidem |
| US5912246A (en) * | 1995-02-15 | 1999-06-15 | Pharmacia & Upjohn Company | Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases |
| IT1276522B1 (it) * | 1995-04-07 | 1997-10-31 | Elena Benincasa | Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei |
| US6013654A (en) * | 1997-08-14 | 2000-01-11 | Pharmacia & Upjohn Company | Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases |
| AUPP278498A0 (en) | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
| EP1005863A1 (en) * | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
| EP1038875B1 (en) * | 1999-03-25 | 2003-06-04 | Synthon B.V. | Imidazopyridine derivatives and process for making them |
| ATE297924T1 (de) * | 1999-03-25 | 2005-07-15 | Synthon Bv | Zolpidem salze |
| US6333345B1 (en) | 1999-05-14 | 2001-12-25 | Sepracor, Inc. | Methods of using and compositions comprising N-desmethylzolpidem |
| US6399621B1 (en) | 1999-08-10 | 2002-06-04 | American Cyanamid Company | N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| US20030091632A1 (en) * | 1999-08-26 | 2003-05-15 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| US6485746B1 (en) | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| US6384221B1 (en) | 1999-09-02 | 2002-05-07 | Neurocrine Biosciences, Inc. | Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| AU5066101A (en) * | 2000-04-13 | 2001-10-30 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
| ATE335481T1 (de) * | 2000-04-24 | 2006-09-15 | Teva Pharma | Zolpidem hemitartrat solvat |
| EP1473036B1 (en) | 2000-04-24 | 2006-08-09 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrate solvate |
| US6723332B2 (en) | 2000-05-26 | 2004-04-20 | Neurogen Corporation | Oxomidazopyridine-carboxamides |
| AU2001270297A1 (en) * | 2000-06-30 | 2002-01-14 | Neurogen Corporation | 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands |
| IT1318624B1 (it) | 2000-07-14 | 2003-08-27 | Dinamite Dipharma S P A In For | Processo per la preparazione di 2-fenil-imidazo (1,2-a)piridin-3-acetammidi. |
| US6514969B2 (en) * | 2000-08-16 | 2003-02-04 | Boehringer Ingelheim Pharma Kg | β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions |
| DE10040016A1 (de) * | 2000-08-16 | 2002-02-28 | Boehringer Ingelheim Pharma | Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| AU2000264428A1 (en) * | 2000-08-17 | 2002-02-25 | Cilag A.G. | Process for the preparation of imidazopyridines |
| WO2002018303A2 (en) * | 2000-08-29 | 2002-03-07 | Ranbaxy Laboratories Limited | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide, a key intermediate of zolpidem |
| US6596731B2 (en) | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
| DE10117183A1 (de) * | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
| KR100433502B1 (ko) * | 2001-10-10 | 2004-06-07 | 철 양 | 확장부가 형성된 종이컵 |
| DE10247271A1 (de) * | 2002-10-10 | 2004-08-26 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yle |
| MXPA05006438A (es) * | 2002-12-18 | 2005-09-08 | Mallinckrodt Inc | Derivados de acetamidas de heteroarilo. |
| WO2004066930A2 (en) * | 2003-01-27 | 2004-08-12 | Arthur Zaks | Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives |
| US20040241100A1 (en) * | 2003-03-17 | 2004-12-02 | Fabre Kramer Pharmaceutical, Inc. | Nasally administrable compositions of zolpidem and methods of use |
| WO2005010002A1 (en) * | 2003-07-31 | 2005-02-03 | Ranbaxy Laboratories Limited | Process for the synthesis of zolpidem |
| WO2005044818A2 (en) * | 2003-10-28 | 2005-05-19 | Sepracor, Inc. | Imidazo[1,2-a]pyridine anxiolytics |
| PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
| KR20140104986A (ko) * | 2004-02-17 | 2014-08-29 | 트랜스셉트 파마슈티칼스, 인코포레이티드 | 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법 |
| JP2007523165A (ja) | 2004-02-18 | 2007-08-16 | セプレイコー インコーポレイテッド | 睡眠の質を改善するためのドーパミン作動薬併用療法 |
| US20080262025A1 (en) * | 2004-07-16 | 2008-10-23 | Yatendra Kumar | Processes for the Preparation of Zolpidem and its Hemitartrate |
| US20060084806A1 (en) * | 2004-07-21 | 2006-04-20 | Ramasubramanian Sridharan | Processes for the preparation of imidazo[1,2-a] pyridine derivatives |
| FR2874611B1 (fr) * | 2004-08-31 | 2006-11-17 | Servier Lab | Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
| NZ563979A (en) * | 2005-05-25 | 2011-02-25 | Transcept Pharmaceuticals Inc | Solid compositions and methods for treating middle-of-the night insomnia |
| US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
| US20070020333A1 (en) * | 2005-07-20 | 2007-01-25 | Chin-Chih Chiang | Controlled release of hypnotic agents |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8148393B2 (en) | 2005-11-18 | 2012-04-03 | Synthon Bv | Zolpidem tablets |
| EP1803722A1 (en) | 2006-01-03 | 2007-07-04 | Ferrer Internacional, S.A. | Imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof |
| US8309104B2 (en) * | 2006-03-02 | 2012-11-13 | Watson Pharmaceuticals, Inc. | Oral controlled release formulation for sedative and hypnotic agents |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| AU2007256893A1 (en) * | 2006-06-05 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted imidazopyridine compounds with hypnotic effects |
| RU2468014C2 (ru) * | 2006-08-24 | 2012-11-27 | Острэйлиен Ньюклиар Сайенс Энд Текнолоджи Организейшн | Фторсодержащие лиганды для нацеливания периферических бензодиазепиновых рецепторов |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080145425A1 (en) * | 2006-12-15 | 2008-06-19 | Pliva Research & Development Limited | Pharmaceutical composition of zolpidem |
| US20090076066A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched zolpidem |
| AU2008314870A1 (en) * | 2007-10-24 | 2009-04-30 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
| US20090169618A1 (en) * | 2007-12-26 | 2009-07-02 | Limor Ari-Pardo | Zolpidem pharmaceutical compositions |
| AU2009284695A1 (en) * | 2008-08-19 | 2010-02-25 | The University Of Sydney | Novel compounds and their uses in diagnosis |
| WO2010045615A2 (en) | 2008-10-16 | 2010-04-22 | Cenomed Biosciences, Llc | Treatment of organophosphate exposure with ocinaplon |
| WO2010074753A1 (en) | 2008-12-23 | 2010-07-01 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2010122576A1 (en) | 2009-04-20 | 2010-10-28 | Matrix Laboratories Ltd | Improved process for the preparation of 6-methyl-2-[4-methyl phenyl] imidazo [1, 2-a] pyridine-3-n, n-dimethyl acetamide. |
| CN102234275B (zh) * | 2010-04-27 | 2015-12-16 | 溧阳合誉药物科技有限公司 | 治疗失眠的氘代咪唑并[1,2-a]吡啶衍生物、制备方法及其应用 |
| US8741888B2 (en) | 2010-11-09 | 2014-06-03 | Carl A. Forest | Sleep aid composition and method |
| WO2015011722A2 (en) * | 2013-07-22 | 2015-01-29 | 3A Chemie Private Limited | Zolpidem, method of preparation and an intermediate therein |
| EP3239150B1 (en) | 2014-12-24 | 2020-02-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3468545A4 (en) | 2016-06-08 | 2020-07-22 | President and Fellows of Harvard College | METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME AND FRAGILE X SYNDROME |
| WO2019189945A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| AU2019272778B2 (en) | 2018-05-22 | 2024-10-03 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| AU2019279858A1 (en) * | 2018-05-29 | 2020-11-26 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
| EP3946390A4 (en) | 2019-03-25 | 2022-12-21 | President and Fellows of Harvard College | COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3336194A (en) * | 1963-04-30 | 1967-08-15 | Merck & Co Inc | Indolyl acid amides |
| GB1076089A (en) * | 1965-11-09 | 1967-07-19 | Selvi & C Lab Bioterapico | New derivatives of imidazo [1,2-a]-pyridine and a process for the manufacture thereof |
-
1980
- 1980-10-22 FR FR8022537A patent/FR2492382A1/fr active Granted
-
1981
- 1981-10-15 AT AT81401606T patent/ATE7393T1/de active
- 1981-10-15 DE DE8181401606T patent/DE3163524D1/de not_active Expired
- 1981-10-15 EP EP81401606A patent/EP0050563B1/fr not_active Expired
- 1981-10-15 LU LU88228C patent/LU88228I2/xx unknown
- 1981-10-19 MX MX81101627U patent/MX6463E/es unknown
- 1981-10-21 IE IE2470/81A patent/IE51686B1/en not_active IP Right Cessation
- 1981-10-21 GR GR66315A patent/GR74701B/el unknown
- 1981-10-21 DK DK465181A patent/DK154429C/da not_active IP Right Cessation
- 1981-10-21 NZ NZ198722A patent/NZ198722A/xx unknown
- 1981-10-21 US US06/313,601 patent/US4382938A/en not_active Expired - Lifetime
- 1981-10-21 NO NO813551A patent/NO155664C/no not_active IP Right Cessation
- 1981-10-21 AU AU76687/81A patent/AU544345B2/en not_active Expired
- 1981-10-21 JP JP56169392A patent/JPS5798283A/ja active Granted
- 1981-10-21 FI FI813288A patent/FI71143C/fi not_active IP Right Cessation
- 1981-10-21 CA CA000388385A patent/CA1157470A/en not_active Expired
- 1981-10-21 ZA ZA817297A patent/ZA817297B/xx unknown
- 1981-10-21 ES ES506412A patent/ES8207537A1/es not_active Expired
- 1981-10-21 IL IL64091A patent/IL64091A/xx not_active IP Right Cessation
- 1981-10-21 PT PT73863A patent/PT73863B/pt unknown
-
1982
- 1982-04-21 OA OA57664A patent/OA07076A/xx unknown
-
1983
- 1983-02-10 US US06/465,605 patent/US4460592A/en not_active Expired - Lifetime
-
1993
- 1993-05-28 NL NL930044C patent/NL930044I2/nl unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011026299A (ja) * | 2009-06-25 | 2011-02-10 | Takada Seiyaku Kk | ゾルピデム酒石酸塩含有内用液剤 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS637545B2 (enExample) | ||
| US6140372A (en) | Acyl derivatives of melatonin and of melatoninergic analogues and their use as medicinal products | |
| JP6704421B2 (ja) | Ｄｎａアルキル化剤 | |
| JPH07502742A (ja) | Ｐａｆ−レセプタ拮抗剤としてのアミノ酸誘導体 | |
| JPS6147485A (ja) | ３‐アシルアミノメチルイミダゾ［１，２‐ａ］ピリジン誘導体 | |
| US4501745A (en) | Anxiolytic imidazo[1,2-a]pyridine derivatives | |
| JPH0412270B2 (enExample) | ||
| JP2010523725A (ja) | 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン | |
| BR112020021329A2 (pt) | inibidores de stat3 | |
| KR910000416B1 (ko) | 벤족사졸리논 유도체의 제조방법 | |
| EP0271040A2 (de) | Neue Pyrrolobenzimidazole, Verfahren zu ihrer Herstellung, sowie Arzneimittel | |
| DE69122427T2 (de) | Imidazonaphthyridinderivate | |
| DE3818830A1 (de) | Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel | |
| EP0874849B1 (en) | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives | |
| JP4917428B2 (ja) | ２−置換フェニル−５，７−ジアルキル−３，７−ジヒドロピロロ［２，３−ｄ］ピリミジン−４−オン誘導体、その製法およびその医薬用途 | |
| PT87604B (pt) | Processo para a preparacao de agentes anti-alergicos e anti-inflamatorios di-hidropiridinicos | |
| SU1297724A3 (ru) | Способ получени производных флуорена | |
| JP3083544B2 (ja) | 心疾患を予防または治療する薬剤 | |
| DE69322673T2 (de) | Imidazopyridazine als Antiasthmatika | |
| JP2002506867A (ja) | 催眠性β−カルボリン誘導体、その製造方法とその医薬品としての用途 | |
| GB1562800A (en) | Fused pyridodiazepines | |
| Hawes et al. | 2, 3-Disubstituted 1, 6-naphthyridines as potential diuretic agents | |
| CA2049490A1 (en) | Pyrrolobenzimidazoles, imidazobenzoxazinones and imidazoquinolones, process for their preparation and their use and preparations containing the compounds | |
| EP0207483B1 (de) | Neue Benzimidazole, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel sowie Zwischenprodukte | |
| EP0934257B1 (en) | Substituted n-arylmethylamino derivatives of cyclobutene-3,4-diones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |